Adult stem cells do not appear to accelerate graft-to-bone healing in ACL reconstruction .
This report has been verified
by one or more authors of the
original publication.
Questo studio è stato identificato come potenzialmente ad alto impatto.
La metrica High Impact di OE, guidata dall'AI, stima l'influenza che un articolo potrebbe avere integrando i segnali della rivista in cui è stato pubblicato e il contenuto scientifico dell'articolo stesso.
Sviluppato utilizzando un'elaborazione del linguaggio naturale all'avanguardia, il modello High Impact di OE prevede in modo più accurato la futura performance citazionale di uno studio rispetto al solo fattore di impatto della rivista.
Ciò consente di riconoscere prima le ricerche clinicamente significative e aiuta i lettori a concentrarsi sugli articoli che hanno maggiori probabilità di influenzare la pratica futura.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2014;2(8):38 Knee Surg Sports Traumatol Arthrosc. 2014 Jan;22(1):66-71. doi: 10.1007/s00167-012-2279-9. Epub 2012 Nov 2.43 patients undergoing anterior cruciate ligament (ACL) surgery using a hamstring graft were randomly assigned to a stem cell or a control group to evaluate the effect of stem cells on graft-to-bone healing. In the study, adult non-cultivated bone marrow stem cells were harvested from select patients and intra-operatively delivered in and around the femoral end of the graft. Upon analysis, the non-cultivated bone marrow stem cells did not appear to advance graft-to-bone healing in ACL reconstruction at 3 months post-operative.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Sì = 1
Incerto = 0,5
Non rilevante = 0
No = 0
La valutazione dei criteri di segnalazione valuta la trasparenza con cui gli autori riportano le caratteristiche metodologiche e sperimentali dello studio all'interno della pubblicazione. La valutazione è suddivisa in cinque categorie che vengono presentate di seguito.
1/4
Randomization
4/4
Outcome Measurements
1/4
Inclusion / Exclusion
4/4
Therapy Description
3/4
Statistics
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
L'Indice di Fragilità è uno strumento che aiuta l'interpretazione dei risultati significativi, fornendo una misura della forza di un risultato. L'Indice di Fragilità rappresenta il numero di eventi consecutivi che devono essere aggiunti a un risultato dicotomico per rendere il risultato non più significativo. Un numero piccolo rappresenta un risultato più debole, mentre un numero grande rappresenta un risultato più forte.
Perché questo studio era necessario ora?
In anterior cruciate ligament (ACL) reconstruction, healing of the tendon graft to the bone is crucial for a successful surgery. Recent research has explored the use of growth factors and stem cells to improve and enhance osteointegration of the graft within the bone tunnel, and avoid complications such as tendon pullout out, which can occur even up to a few months postoperatively. The aim of this study was to determine if non-cultivated adult bone marrow mesenchymal stem cells (BMSCs) could enhance tendon-to-bone healing in the femoral tunnel following ACL reconstruction using a hamstring graft.
Qual era la domanda di ricerca principale?
Are adult non-cultivated bone marrow stem cells able to accelerate tendon-to-bone healing in the femoral tunnel, measured approximately 3 months after ACL reconstruction?
- On PDW-FatSat images, there was no significant difference between the experimental vs. control group in median SNR of the upper interzone [12.3 (7.6-14.6) vs. 10.6 (8.7-13.1)] and lower interzone [10.4 (8.3-13.3) vs.12.4 (10.6-13.4)] (p>0.05).
- On T1W-FatSat-Gad images, there was no significant difference between the experimental vs. control group in median SNR of the upper interzone [22.3 (17.5-27.8) vs. 22.5 (18.8-31.0)] and lower interzone [21.8 (18.1-26.1) vs. 24.5 (21.1-33.5)] (p>0.05).
- A graft biopsy from one patient in each group revealed no apparent differences in collagen amount, vascularity, and number of cells between samples. Both patients were chosen for biopsies because they required second-look arthroscopy for meniscectomy at 4 months.
Che cosa devo ricordare di più?
From the results obtained in this study, graft-to-bone healing after ACL reconstruction does not appear to be expedited with the use of adjuvant adult non-cultivated bone marrow mesenchymal stem cells (BMSCs).
Come influenzerà l'assistenza ai miei pazienti?
While it appears stem cells do not accelerate graft to bone healing in ACL reconstruction, larger trials are required to confirm these results. Furhermore, it should be noted that MRI evaluation may not be sensitive enough to detect histological changes at the tendon-to-bone interface. Future studies are needed to further evaluate the efficacy of this augmentative therapy.
DISCLAIMER
Il contenuto di questa pagina è solo a scopo informativo e non intende sostituire la consulenza, la diagnosi o il trattamento medico professionale. Se ha bisogno di cure mediche, si rivolga sempre al suo medico o al pronto soccorso più vicino. Le opinioni, le convinzioni e i punti di vista espressi dalle persone sui contenuti presenti in questa pagina non riflettono le opinioni, le convinzioni e i punti di vista di OrthoEvidence.
